Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond.
作者： Maju Mathew Koola , None
DOI: 10.1016/J.PSYCHRES.2020.113409
关键词: Memantine 、 Disease 、 Internal medicine 、 Allosteric modulator 、 Galantamine 、 Medicine 、 Aducanumab 、 Randomized controlled trial 、 Oncology 、 Dementia 、 Acetylcholinesterase inhibitor
摘要: Abstract Alzheimer's disease (AD) is the most prevalent form of dementia in elderly population worldwide. Despite major unmet clinical need, no new medications for treatment AD have been approved since 2003. Galantamine an acetylcholinesterase inhibitor that also a positive allosteric modulator at α4β2 and α7nACh receptors. Memantine is N-methyl- d -aspartate receptor modulator/agonist. Both galantamine memantine are FDA-approved AD. The objective this review to highlight potential galantamine-memantine combination conduct randomized controlled trials (RCTs) Several studies shown be effective. Neurodegenerative diseases involve multiple pathologies; therefore, appears rational approach. Although underutilized, standard care Positive RCTs with concurrent improvement symptoms biomarkers may lead FDA approval, which greater utilization practice.
sci-hub.st 参考文章(156)
Michael Spedding, New directions for drug discovery. Dialogues in clinical neuroscience. ,vol. 8, pp. 295- 301 ,(2006)
Stephen I. Deutsch, Jessica A. Burket, Andrew D. Benson, Maria R. Urbano, The 15q13.3 deletion syndrome: Deficient α(7)-containing nicotinic acetylcholine receptor-mediated neurotransmission in the pathogenesis of neurodevelopmental disorders. Progress in Neuro-psychopharmacology & Biological Psychiatry. ,vol. 64, pp. 109- 117 ,(2016) , 10.1016/J.PNPBP.2015.08.001
Ruiqing Ni, Amelia Marutle, Agneta Nordberg, Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain. Journal of Alzheimer's Disease. ,vol. 33, pp. 841- 851 ,(2013) , 10.3233/JAD-2012-121447
Paul M. Matthews, Eugenii A. Rabiner, Jan Passchier, Roger N. Gunn, Positron emission tomography molecular imaging for drug development. British Journal of Clinical Pharmacology. ,vol. 73, pp. 175- 186 ,(2012) , 10.1111/J.1365-2125.2011.04085.X
Diana Jerusalinsky, Edgar Kornisiuk, Iván Izquierdo, Cholinergic Neurotransmission and Synaptic Plasticity Concerning Memory Processing Neurochemical Research. ,vol. 22, pp. 507- 515 ,(1997) , 10.1023/A:1027376230898
Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis American Journal of Psychiatry. ,vol. 154, pp. 165- 172 ,(1997) , 10.1176/AJP.154.2.165
Tonali Blanco Ayala, Rafael Lugo Huitrón, Liliana Carmona Aparicio, Daniela Ramírez Ortega, Dinora González Esquivel, José Pedraza Chaverrí, Gonzalo Pérez de la Cruz, Camilo Ríos, Robert Schwarcz, Verónica Pérez de la Cruz, Alternative kynurenic acid synthesis routes studied in the rat cerebellum Frontiers in Cellular Neuroscience. ,vol. 9, pp. 178- 178 ,(2015) , 10.3389/FNCEL.2015.00178
Hailong Zhang, Tao Li, Shupeng Li, Fang Liu, Cross-talk between α7 nAchR and NMDAR revealed by protein profiling. Journal of Proteomics. ,vol. 131, pp. 113- 121 ,(2016) , 10.1016/J.JPROT.2015.10.018
Kosuke Matsuzono, Nozomi Hishikawa, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Yumiko Nakano, Koji Abe, Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study. Journal of Alzheimer's Disease. ,vol. 45, pp. 771- 780 ,(2015) , 10.3233/JAD-143084
Sheng-Yu Lee, Shiou-Lan Chen, Yun-Hsuan Chang, Po See Chen, San-Yuan Huang, Nian-Sheng Tzeng, Yu-Shan Wang, Liang-Jen Wang, I Hui Lee, Tzu-Yun Wang, Tzung Lieh Yeh, Yen Kuang Yang, Jau-Shyong Hong, Ru-Band Lu, The Effects of Add-On Low-Dose Memantine on Cytokine Levels in Bipolar II Depression Journal of Clinical Psychopharmacology. ,vol. 34, pp. 337- 343 ,(2014) , 10.1097/JCP.0000000000000109